Chiome Bioscience (TSE:4583) Liabilities-to-Assets : 0.29 (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Chiome Bioscience Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Chiome Bioscience's Total Liabilities for the quarter that ended in Mar. 2024 was 円506.4 Mil. Chiome Bioscience's Total Assets for the quarter that ended in Mar. 2024 was 円1,753.9 Mil. Therefore, Chiome Bioscience's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.29.

Chiome Bioscience Liabilities-to-Assets Historical Data

The historical data trend for Chiome Bioscience's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiome Bioscience Liabilities-to-Assets Chart

Chiome Bioscience Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Liabilities-to-Assets

Get a 7-Day Free Trial

0.07

0.11

0.19

0.34

Chiome Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Liabilities-to-Assets	Get a 7-Day Free Trial															0.25	0.32	0.31	0.34	0.29

Competitive Comparison of Chiome Bioscience's Liabilities-to-Assets

For the Biotechnology subindustry, Chiome Bioscience's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chiome Bioscience's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Liabilities-to-Assets falls into.

Chiome Bioscience Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Chiome Bioscience's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )	=	Total Liabilities	/	Total Assets
	=	593.731	/	1751.454
	=	0.34

Chiome Bioscience's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )	=	Total Liabilities	/	Total Assets
	=	506.367	/	1753.934
	=	0.29

Chiome Bioscience (TSE:4583) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Chiome Bioscience Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Chiome Bioscience's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiome Bioscience (TSE:4583) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiome Bioscience Inc (TSE:4583) » Definitions » Liabilities-to-Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071

Website

http://www.chiome.co.jp

Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Chiome Bioscience (TSE:4583) Headlines

No Headlines